Bempedoic acid (Nilemdo) is a new lipid﹍owering therapy for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia. This article summarises its mechanism of action, clinical trial efficacy and side〆ffects.doi:10.1002/psb.1888Steve Chaplin...
2004年3月前,美国Esperion制药公司就致力于调节血脂异常药物的研发工作,研制与开发一种先导候选产品:三磷酸腺苷(ATP)-柠檬酸裂合酶(ATP-citrate lyase,ACL)抑制药——bempedoic acid (贝培多酸),用于降低内源性胆固醇,并通过上调LDL受体降低LDL-C水平升高,减轻肌肉相关副作用。除了作为单一疗法的贝培多酸片剂之外,...
5%(95%CI: -21. 0%~-13. 9%,P<0. 001).此外,与安慰剂组相 比,Bempedoic Acid 显著降低了非高密度脂蛋白胆 固醇(non-high density lipoprotein cholesterol,non- HDL-C)水平(-10. 8% vs. 2. 3%),差异为 -13. 0% (95%CI:-16. 3%~ -9. 8%,P<0. 001);Bempedoic Acid 显著降低了总...
and the molecular weight is 344.5 grams per mole. Bempedoic acid is a white to off-white crystalline powder that is highly soluble in ethanol, isopropanol and pH 8.0 phosphate buffer, and insoluble in water and aqueous solutions below pH 5. ...
Bempedoic acid (Nexletol; Esperion) and bempedoic acid and ezetimibe (Nexlizet; Esperion) are the only LDL-C lowering non-statin drugs indicated for primary prevention patients.
Bempedoic acid (ETC-1002),also known as Bempedoic acid, is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies.ETC-1002 is an
Because of its special mechanism, it has a special place in the management of lipids, especially for patients who cannot take statins or who need additional medication to have the best cholesterol control. Bempedoic acid-containing effective hyperlipidemia treatments are predicted to become more in de...
The Type II(a) variation application in Europe marks the culmination of Esperion's landmarkCholesterolLowering via bempedoic acid, anACL-InhibitingRegimen (CLEAR) Outcomes trial in which NILEMDO demonstrated significant cardiovascular risk reduction across a range of important clinical events including a...
Bempedoic acid – a new alternative to statin? Statin is well-known for the competitive inhibitory action on the active site of hepatic HMG-CoA reductase, the rate-limiting enzyme in mevalonate pathway of cholesterol synthesis. This leads to reduced generation of mevalonic acid [40]. Bempedoic ac...
Bempedoic Acid (BA) is a first-in-class inhibitor of ATP-citrate lyase (ACL), upstream of the HMG-CoA reductase in the cholesterol biosynthetic pathway, resulting in decreases in LDL-cholesterol and apolipoprotein B [[4], [6], [8]]. Additionally, BA in combination with ezetimibe ...